Autoimmunity to Annexin A2 predicts mortality among hospitalised COVID-19 patients

Marisol Zuniga, Claudia Gomes, Steven E. Carsons, Michael T. Bender, Paolo Cotzia, Qing Robert Miao, David C. Lee, Ana Rodriguez


This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©The authors 2021. This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org
Autoimmunity to Annexin A2 Predicts Mortality Among Hospitalized COVID-19 Patients

**Authors:**
*Marisol Zuniga*
*Claudia Gomes, PhD*
Steven E. Carson, MD
Michael T. Bender, MD
Paolo Cotzia, MD
Qing Robert Miao, PhD
**David C. Lee, MD, MS**
**Ana Rodriguez, PhD**

* Authors contributed equally to this work
** Authors contributed equally to this work

**Author Affiliations:**
1) Department of Microbiology, NYU Grossman School of Medicine
2) Division of Rheumatology, Department of Medicine, NYU Long Island School of Medicine
3) Division of Pulmonology and Critical Care Medicine, Department of Medicine, NYU Long Island School of Medicine
4) Department of Pathology, NYU Grossman School of Medicine
5) Department of Foundations of Medicine, NYU Long Island School of Medicine
6) Department of Emergency Medicine, NYU Grossman School of Medicine
7) Department of Population Health, NYU Grossman School of Medicine

**Corresponding Authors:**
Ana Rodriguez, PhD
430 East 29th Street
New York, NY 10016
Email: Ana.Rodriguez@nyumc.org / Phone: 646-501-6997

David C. Lee, MD, MS
227 East 30th Street
New York, NY 10016
Email: David.Lee@nyumc.org / Phone: 212-562-6561

**Take Home Message:** Levels of anti-Annexin A2 antibodies at admission strongly predicted mortality among hospitalized COVID-19 patients. Given its critical protective function in the lung, Annexin A2 antagonism may play an important role in the pathophysiology of COVID-19.
The pathophysiology of severe COVID-19 has largely been attributed to a hyper-inflammatory response without a clear indication of the underlying mechanism.[1] There is a characteristic delay in the onset of respiratory distress, approximately 6 to 12 days after the start of symptoms, which is somewhat atypical for other severe viral respiratory infections.[2] Several theories have been proposed for this delay such as an indolent infection or viral persistence. However, data from viral cultures of SARS-CoV-2 (not PCR) demonstrates a lack of positive cultures beyond day 9 of illness.[3]

The timing of respiratory distress due to COVID-19 notably coincides with the onset of the humoral immune response, and there is evidence of autoantibodies among hospitalized COVID-19 patients including anti-interferon and antiphospholipid antibodies.[4, 5] The pathogenicity of these autoantibodies is unclear. However, a pivotal study demonstrated high levels of extrafollicular B cell activation among severe cases of COVID-19.[6] This type of immune response is characteristic of several autoimmune diseases, which raises the question whether severe COVID-19 is the result of a catastrophic autoimmune response that occurs among a subset of patients infected by the SARS-CoV-2 virus.[7]

This study investigated the possibility that COVID-19 patients have autoimmune antibodies to Annexin A2, a protective protein expressed in the lung and other organs. Since this phospholipid-binding protein is critical for fibrinolysis, lung elasticity, cell membrane repair, and integrity of the pulmonary vasculature, antagonism of Annexin A2 may explain many of the hallmark clinical features of severe COVID-19 cases.[8]

To evaluate this possibility, we analyzed patient plasma on hospital day 0 or 1 among 86 patients at NYU Langone Health who were hospitalized for COVID-19 and confirmed to be positive by PCR. Anti-Annexin A2 IgG antibodies were measured by ELISA. For comparison, we
also studied IgG antibodies directed against Annexin A5, which is another target of prothrombotic antiphospholipid antibodies, but is not known to have a direct role in maintaining the integrity of the pulmonary vasculature.[9] Antibody levels were calculated as relative units (RU) using a plasma sample previously identified as a high responder for IgG autoantibodies. Patients were categorized as 1) non-critical if hospitalized, but not intubated, 2) critically ill if hospitalized and intubated, or 3) died from COVID-19 during their hospitalization.

After a descriptive analysis of study population, we analyzed the anti-Annexin A2 and A5 antibodies levels as stratified by disease severity using ANOVA. To perform our primary analysis, we tested the association between antibody levels and death using multivariable logistic regression, adjusting for age, sex, race, and history of hypertension, diabetes, and obesity (BMI > 30 kg/m2). A p-value of 0.025 was used to account for multiple comparisons. We used a margins analysis to graphically display mortality risk at a range of antibody levels. An analysis of outliers was performed to ensure that there were not extreme values for antibody levels that had an undue influence on the results. In addition, the robustness of the association between antibody levels and death was assessed with a sensitivity analysis that included the maximum laboratory values over the course of the hospitalization for these COVID-19 patients. These commonly performed tests included white blood cell count (WBC), aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine kinase (CK), lactate dehydrogenase (LDH), C-reactive protein (CRP), ferritin, and D-dimer.

All statistical analyses were performed in Stata 16.2. Patients consented to use of their biospecimens for COVID-19 research through a central biorepository and protocol approved by the NYU IRB. A more detailed description of the methods can be accessed in a preprint of this study.[10]
Of the 86 patients in our study, 28 were non-critical, 36 were critically ill, and 22 died. Those who died had higher rates of hypertension (p=0.04) and obesity (p=0.05) when compared to patients who survived. In analyzing the WBC, AST, ALT, CK, LDH, CRP, ferritin, and D-dimer values among these hospitalized COVID-19 patients, the maximum values increased as expected by disease severity (p<0.01). We found higher average levels of anti-Annexin A2 IgG antibodies among the hospitalized COVID-19 patients who died (1.16 RU, 95% confidence interval (CI): 0.95-1.37) when compared with the non-critical (0.80 RU 95% CI: 0.66-0.94) and critically ill hospitalized COVID-19 patients (0.89 RU, 95% CI: 0.77-1.01). In comparison, there was no statistically significant difference in the average levels of anti-Annexin A5 IgG antibodies when stratified by disease severity (p=0.32).

In our primary analysis of mortality among the 86 hospitalized COVID-19 patients, we found that anti-Annexin A2 antibody levels strongly predicted death after adjustment for age, sex, race, and comorbidities with an odds ratio of 9.3 per RU (CI: 1.9-44.6, p=0.005). In comparison, anti-Annexin A5 antibody levels were not associated with a higher mortality rate (CI: 0.5-15.2, p=0.22). Using a margins analysis, we graphically depicted predicted mortality rates across a range of levels for anti-Annexin A2 antibodies (Figure 1). In our sensitivity analysis, we added adjustments for the maximum WBC, AST, ALT, CK, LDH, CRP, ferritin, and D-dimer levels. This multivariable regression demonstrated that anti-Annexin A2 antibody levels strongly predicted mortality with an odds ratio of 12.9 per RU (CI: 1.5-108.7, p=0.019) even after adjustment for the maximum laboratory abnormalities during the hospitalization of these COVID-19 patients.

Our study finds evidence of higher levels of IgG antibodies directed against Annexin A2 among COVID-19 patients who died. More importantly, anti-Annexin A2 antibody levels strongly predicted mortality after controlling for patient risk factors and for the maximum levels of key laboratory markers associated with severe COVID-19.
Autopsy evidence demonstrates that severe cases of COVID-19 have extensive thrombotic disease, diffuse alveolar damage, and endothelial disruption that leads to pulmonary edema and fibrin deposition.[11] These findings correlate with the clinical manifestations of severe COVID-19, which include diffuse clotting, adult respiratory distress syndrome (ARDS), non-cardiogenic pulmonary edema, and fibrinous pulmonary exudates generally without bacterial superinfection.[1] Though our study does not present any direct evidence of the pathogenicity of these autoantibodies, antagonism of Annexin A2 would explain many of the clinical findings that are characteristic of patients with severe COVID-19.

Annexin A2 is critical for fibrinolysis in the lung by acting as a co-receptor that activates endogenous tissue plasminogen activator (t-PA) to lyse clots and promote fibrin clearance.[8] More recently, Annexin A2 was found to maintain the endothelial cell junctions in the lung microvasculature, preventing pulmonary edema especially in response to hypoxia.[12] Finally, Annexin A2 promotes lung elasticity and is also involved cell membrane stabilization and repair of pulmonary epithelial cells, thereby preventing apoptosis.[13] Its inhibition might also explain the diffuse alveolar damage, ARDS, and pulmonary fibrosis seen in severe cases of COVID-19.

Notably, prior studies of SARS-CoV-1 identified autoantibodies that were cytotoxic to lung epithelial and endothelial cells and also specifically targeted Annexin A2 among hospitalized SARS patients.[14] Loss of immune tolerance and a catastrophic autoimmune insult among a subset of patients could explain why certain patients develop severe symptoms of COVID-19.[15] Other patients without this autoimmune response may have less severe symptoms consistent with other coronavirus infections which only cause asymptomatic or mild disease.
While these autoantibodies could be non-specific markers of lung injury, it is critical to explore the pathogenicity of these anti-Annexin A2 antibodies, as they could explain the underlying pathophysiology of severe COVID-19. Additional studies should assess the specificity of these autoantibodies to COVID-19 by investigating whether they also occur in other respiratory diseases such as influenza or other types of ARDS. Furthermore, we believe that the persistence of these anti-Annexin A2 antibodies should be studied, especially among Long COVID patients with persistent respiratory symptoms.
This research was supported by an internal grant from the NYU Langone COVID-19 Special Fund. We want to specifically thank the Center for Biospecimen Research and Development at the NYU School of Medicine, Brian Fallon for bioinformatics support, and all of the volunteers that helped to obtain and process the samples used in this study and other research related to COVID-19.

Contributions: A.R. and D.C.L. designed the study. M.Z. and C.G. performed the experiments. A.R. and P.C. collected the data and identified patient samples at NYU Langone Health. D.C.L. drafted the manuscript and performed the statistical analyses. All authors interpreted the data and provided critical input to the manuscript. None of the authors have any conflicts of interest to disclose.
REFERENCES


**Figure 1: Prediction of Mortality Based on Anti-Annexin A2 Antibody Levels**

Legend: Margins analysis based on logistic regression results depicts predicted mortality across a range of anti-Annexin A2 antibody levels in relative units (RU). Error bars depict 95% confidence intervals.